#Japan #Tokyo #stem cell #HOPECELL

Celebrating HOPECELL's First Anniversary with an Exciting Campaign

In the heart of Tokyo, the Stem Cell Research Institute is marking the first anniversary of its innovative service, HOPECELL. Since its launch, this service has gained popularity among expectant mothers, with around 10,000 women opting to store their baby's cord blood and tissue for future medical use.

What is HOPECELL?

HOPECELL stands out as Japan's only service that allows the storage of both umbilical cord blood and tissue. This unique offering means that families have a higher chance of preserving vital stem cells that can potentially be used in the treatment of various medical conditions.

More than just a storage service, HOPECELL is engineered to provide peace of mind to families. For a manageable monthly fee starting from just 2,980 yen, parents can secure their child’s stem cells without incurring additional fees for installment payments. This flexibility makes it easier for families to consider the benefits of using HOPECELL.

Special Anniversary Campaign

To celebrate its successful year, HOPECELL is launching a limited-time campaign from December 19, 2025, to March 31, 2026. During this promotional period, anyone who contracts the HOPECELL service will receive a significant discount: five years of storage fees will be waived for contracts of 10 years or 20 years, amounting to a potential saving of up to 66,000 yen. This offer is inclusive of tax and based on a 120-month installment plan.

The Significance of Cord Blood and Tissue

The cord blood collected during childbirth is rich in stem cells, which have garnered interest for their potential in innovative medical treatments. Recent clinical studies utilize cord blood to explore therapies for cerebral palsy and autism spectrum disorders. Additionally, the cord blood serves as a source for generating autologous induced pluripotent stem (iPS) cells, hinting at a promising future in personalized medicine.

Families can also utilize the stored cord tissue to create a “Family Supernatant®,” a service allowing access to cultivated stem cell solutions for a range of family needs.

Commitment to New Medical Options

The Stem Cell Research Institute operates with the commitment to provide “new medical options for new lives.” With a strong network of maternity facilities, the organization is dedicated to expanding its cell bank services derived from perinatal tissues like umbilical cord blood. They are also actively involved in the development of novel treatments leveraging these precious biological materials.

In addition to its core services, the company is investing in related fields such as regenerative medicine and femtech. The aim is to foster sustainable growth while contributing positively to society.

Company Overview

Founded on August 5, 1999, the Stem Cell Research Institute is publicly listed on the Tokyo Stock Exchange under the ticker 7096. The firm reports a capital of approximately 708 million yen and is led by President Takafumi Shimizu.
Addressing evolving medical needs, HOPECELL and the Stem Cell Research Institute continue to pave the way for advancements in regenerative therapies, enriching lives while offering essential services to families.

For media inquiries, please contact the Stem Cell Research Institute at 03-6811-3235 or via email at [email protected].